Skip to main content

Table 1 Demographic and clinical characteristics

From: Persistence with treatment for Wilson disease: a retrospective study

Variable, n = 170Values
Male:female ratio, n (%)77 (45.3):93 (54.7)
Age, mean ± SD (years)37.5 ± 10.4
Age at diagnosis, mean ± SD (years)25.0 ± 10.0
Time from symptom onset, mean ± SD (months)15.9 ± 14.2
Duration of treatment, mean ± SD (years)11.7 ± 3.2
Predominant clinical form at diagnosis, n (%)
 Hepatic79 (46.5)
 Neurological91 (53.5)
Type of initial treatment, n (%)
 D-penicillamine98 (57.6)
 Zinc sulphate72 (42.4)
Type of treatment during assessment, n (%)
 D-penicillamine76 (44.7)
 Zinc sulphate94 (55.3)
Persistence in drug use, n (%)
 Yes126 (74.1)
 No44 (25.9)
Adverse events, number of subjects (%)53 (31.2)
Outcome of treatment (at the time of assessment), n (%)
 Improvement38 (22.4)
 No change106 (62.4)
 Worsening26 (15.3)
  1. SD standard deviation